A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation

Abstract

Splenic lymphoma with villous lymphocytes (SLVL) or splenic marginal zone lymphoma with circulating villous lymphocytes is rare, and prolymphocytic transformation of SLVL is rarer. At present, only one case of SLVL with t(8;14)(q24;q32) translocation has been reported. In this study, we report a case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) chromosome translocation that we inclined to SLVL with a prolymphocytic transformation. A 73-year-old female showed marked hepatosplenomegaly and high lymphocytosis (lymphocytes>200×10⁹/L). The abnormal lymphocytes had short coarse villi and round nuclei with prominent nucleoli. The immunophenotypes showed CD19⁺, CD20⁺, HLA-DR⁺, CD22⁺, CD5⁺, Kappa⁺, CD25^dim, CD71^dim, Lambda⁻, CD7⁻, CD10⁻, CD23⁻, CD34⁻, CD33⁻, CD13⁻, CD14⁻, CD117⁻, CD64⁻, CD103⁻, and CD11c⁻. The karyotype showed complex abnormality: 46XX,+3,−10, t(8;14)(q24;q32)[11]/46XX[⁹]. The cytoplasmic projection, immunological characteristics, and trisomy 3 chromosome abnormality supported the diagnosis of SLVL. However, the presence of prominent nucleoli and high lymphocytosis suggested prolymphocytic transformation, probably as a result of t(8,14) chromosome translocation. In this report, we described an unusual case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation, which could provide help in the diagnosis and differential diagnosis of B-lymphocytic proliferative diseases.

Keywords

splenic lymphoma with villous lymphocytes / splenic marginal zone lymphoma / transformation / chromosome translocation

References

[1] Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM, Santoja C, Solé F, Sánchez-Beato M, Piris MA. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001; 25(10): 1268–1276

[2] Dungarwalla M, Appiah-Cubi S, Kulkarni S, Saso R, Wotherspoon A, Osuji N, Swansbury J, Cunningham DC, Catovsky D, Dearden CE, Matutes E. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008; 143(1): 71–74

[3] Hoehn D, Miranda RN, Kanagal-Shamanna R, Lin P, Medeiros LJ. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Hum Pathol 2012; 43(11): 1828–1838

[4] Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008; 111(4): 2253–2260

[5] Troussard X, Mauvieux L, Radford-Weiss I, Rack K, Valensi F, Garand R, Vekemans M, Flandrin G, Macintyre EA. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Français d’Hématologie Cellulaire (GFHC) study. Br J Haematol 1998; 101(4): 712–721

[6] Sonu R, Gregg J, Chen M. Splenic marginal zone lymphoma with t(8;14)(q24.1;q32)/MYC rearrangement. J Hematop 2012; 5(3): 141–147

[7] Visser L, Shaw A, Slupsky J, Vos H, Poppema S. Monoclonal antibodies reactive with hairy cell leukemia. Blood 1989; 74(1): 320–325

[8] Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2013; 37(4): 401–409

[9] Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16(1): 41–56

[10] Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X;French Society of Haematology. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol 2014; 93(12): 1977–1983

[11] Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d’Hématologie Cellulaire (GFHC). Br J Haematol 1996; 93(3): 731–736

[12] Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 1994;14 (Suppl 1):57–61

[13] Tierens A, Delabie J, Malecka A, Wang J, Gruszka-Westwood A, Catovsky D, Matutes E. Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am J Pathol 2003; 162(2): 681–689

[14] Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010; 116(9): 1479–1488

[15] Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83(6): 1558–1562

[16] Melo JV, Hegde U, Parreira A, Thompson I, Lampert IA, Catovsky D. Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol 1987; 40(6): 642–651

[17] Melo JV, Wardle J, Chetty M, England J, Lewis SM, Galton DA, Catovsky D. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. III. Evaluation of cell size by morphology and volume measurements. Br J Haematol 1986; 64(3): 469–478

[18] Bearman RM, Pangalis GA, Rappaport H. Prolymphocytic leukemia: clinical, histopathological, and cytochemical observations. Cancer 1978; 42(5): 2360–2372

[19] Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. Chapter 95: Hairy Cell Leukemia. In: Kaushansky K, Lichtman MA, Kipps TJ. Williams Hematology. Eighth Edition. United States: The McGraw-Hill Companies, Inc. 2010; 1485–1486

[20] Heintel D, Streubel B, Welzel N, Le T, Schwarzinger I, Haas OA, Simonitsch I, Lechner K, Jaeger U. Burkitt lymphoma following splenic marginal zone lymphoma: evidence for two independent B-cell clones. Cancer Genet Cytogenet 2003; 141(1): 86–88

[21] Flatley E, Chen AI, Zhao X, Jaffe ES, Dunlap JB, Pittaluga S, Abdullah S, Olson SB, Spurgeon SE, Fan G. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. Am J Clin Pathol 2014; 142(3): 347–354

[22] Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, Diop M, Scourzic L, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Kikushige Y, Davi F, Lambert J, Gautheret D, Merle-Béral H, Sutton L, Dessen P, Solary E, Akashi K, Vainchenker W, Mercher T, Droin N, Ogawa S, Nguyen-Khac F, Bernard OA. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014; 4(9): 1088–1101

[23] Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 2014; 6(238): 238ra71

[24] Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20): 2375–2390

Acknowledgements

This work was supported in part by grants from National Natural Science Foundation of China (No. 81670127) and Natural Science Foundation of Jiangsu Province (No. BK20150474), and Xiaofeng Shi is a member of medical key personnel of Zhenjiang Municipality and young medical personnel of Jiangsu Province.

Compliance with ethics guidelines

Xiaofeng Shi, Rong Ba, Haiyan You, Qian Jiang, Jiansong Huang, Jianhua Mao, Lanxiu Han, Shuo Zhang, Qin Zhuang, Xianqiu Yu, Lixia Wang, Yun Wang, Dongya Li, Wei Zhu, Yong Zhang, Yan Zhu, and Xiaodong Xi declare no conflict of interest in this study. Informed consent was obtained from the patients of the study.

RIGHTS & PERMISSIONS

2017 Higher Education Press and Springer-Verlag GmbH Germany